Tanzawaic Acids, a Chemically Novel Set of Bacterial Conjugation Inhibitors

Bacterial conjugation is the main mechanism for the dissemination of multiple antibiotic resistance in human pathogens. This dissemination could be controlled by molecules that interfere with the conjugation process. A search for conjugation inhibitors among a collection of 1,632 natural compounds,...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 11; no. 1; p. e0148098
Main Authors Getino, María, Fernández-López, Raúl, Palencia-Gándara, Carolina, Campos-Gómez, Javier, Sánchez-López, Jose M, Martínez, Marta, Fernández, Antonio, de la Cruz, Fernando
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 26.01.2016
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Bacterial conjugation is the main mechanism for the dissemination of multiple antibiotic resistance in human pathogens. This dissemination could be controlled by molecules that interfere with the conjugation process. A search for conjugation inhibitors among a collection of 1,632 natural compounds, identified tanzawaic acids A and B as best hits. They specially inhibited IncW and IncFII conjugative systems, including plasmids mobilized by them. Plasmids belonging to IncFI, IncI, IncL/M, IncX and IncH incompatibility groups were targeted to a lesser extent, whereas IncN and IncP plasmids were unaffected. Tanzawaic acids showed reduced toxicity in bacterial, fungal or human cells, when compared to synthetic conjugation inhibitors, opening the possibility of their deployment in complex environments, including natural settings relevant for antibiotic resistance dissemination.
Bibliography:Competing Interests: Jose M. Sánchez-López, Marta Martínez and Antonio Fernández are employed by Biomar Microbial Technologies. Biomar Microbial Technologies and Fernando de la Cruz laboratory were collaborative partners of the grant 282004/FP7-HEALTH-2011-2.3.1-2 "Evolution and transfer of antibiotic resistance" financed by the European Seventh Framework Programme (https://ec.europa.eu/research/fp7). There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Conceived and designed the experiments: AF FdlC. Performed the experiments: MG RFL CPG JCG JMSL MM. Analyzed the data: MG RFL JCG FdlC. Wrote the paper: MG RFL FdlC.
Current address: Department of Molecular Biology and Biochemistry, Drug Discovery Division, Southern Research Institute, Birmingham, Alabama, United States of America
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0148098